Skip to content
Pan-India manufacturing + marketing · HP plant · GMP / GLP / GCP
SURMILAHealth · Innovation · Trust
Home / News Room / R&D
News Room · R&D

R&D pilots extended-release formulation platform

Matrix and reservoir release systems move from the lab toward scalable formulations for selected therapies.

10 July 2026

R&D pilots extended-release formulation platform

R&D pilots extended-release formulation platform

Surmila's R&D team has advanced its extended-release platform, applying matrix and reservoir based release systems to selected molecules. The work is aimed at improving dosing convenience and patient adherence.

Formulation development is supported by analytical method development and validation on HPLC, GC and FTIR, alongside stability studies conducted to ICH guidelines in walk-in chambers.

The platform joins a growing set of in-house technologies, including bioavailability enhancement through solubilisation, complexation and solid dispersion, nano-particle based products, and taste-masking for solid and liquid orals.

These capabilities allow Surmila to make credible inroads into market segments traditionally dominated by technology-protected brands, where formulation know-how matters more than volume alone.

Candidate products are progressing through internal review, with scale-up planned at the Himachal Pradesh facility once development milestones are met.

The team continues to evaluate orodispersible and effervescent technologies for solid orals as part of its forward R&D roadmap.

← All news